You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東曜藥業-B(01875.HK)治療乳腺癌在研藥完成三期註冊臨床試驗首例患者給藥
阿思達克 07-23 12:31
東曜藥業-B(01875.HK)公布,集團自主研發的HER2靶向的在研抗體偶聯藥物(ADC)TAA013於近日達成關鍵性臨床階段里程碑。TAA013已完成關鍵性三期註冊臨床試驗的首例患者給藥,研究的目的是評價TAA013對比拉帕替尼聯合卡培他濱在經曲妥珠單抗治療失敗的、不可切除的局部晚期或轉移性HER2陽性乳腺癌患者中的有效性和安全性。如果成功,研究將用於支持TAA013在中國的新藥上市申請。

集團指,HER2陽性乳腺癌為一種常見的乳腺癌,集團希望本研究結果可以使HER2陽性乳腺癌患者獲益,並給臨床醫生提供更好的治療選擇。而TAA013是一種含有曲妥珠單抗-美坦新衍生物(曲妥珠-MCC-DM1)的在研ADC藥物,旨在成為Kadcyla的實惠替代藥物,用於治療HER2陽性乳腺癌。(ek/u)

~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account